Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India following approval from the country's drug ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

Listen… We are always on the hunt for a deal. Clothes, restaurants, travel, whatever — if there’s a deal out there, we’ll ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety ... a weight loss candidate in pill form. And ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly stock has advanced more than 200% over ... a weight loss candidate in pill form. And Lilly may even submit orforglipron for regulatory approval as early as this year.

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial ...